Clinical Trials Browser

Prostatic Neoplasms, Castration-Resistant × Pluvicto × 90 days × Clear all

NCT07047118 2026-03-02

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant